Judy Garber
Director, of Cancer Genetics and Prevention Disease Center Dana-Farber Cancer Institute · Boston Childrens Hospital
Credentials: · · · · · ·
History
- Present
of Cancer Genetics and Prevention Disease Center Dana-Farber Cancer Institute · Boston Childrens Hospital
- Present
- Present
Division for Cancer Genetics and Prevention · Mass General Brigham
- 1985–1987
- 1984–1985
1977–1981
Research
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
Cell · 1993 · 2,518 citations
Mutational processes molding the genomes of 21 breast cancers
Cell · 2012 · 1,540 citations
The Lancet · 2010 · 1,426 citations
102 papers
101 papers
- KO
85 papers
80 papers
74 papers
72 papers
72 papers
59 papers
Grants
- 2013–2030
Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer
National Cancer Institute · P50
Project lead · $1.2M · Dana-Farber Cancer Inst
- 2022–2027
National Cancer Institute · P50
Project lead · $415.8K · University of Michigan at Ann Arbor
- 2019–2026
Precision Approaches to Refining TP53-Associated Cancer Risk
National Cancer Institute · R01
PI · $8.5M · Beckman Research Institute/City of Hope
- 2010–2016
Discovery, Biology and Risk of Inherited Variants in Breast Cancer
National Cancer Institute · U19
PI · $10.6M · Harvard University d/b/a Harvard School of Public Health
Clinical trials
- 2026–2028
Principal investigator · Not yet recruiting · Phase 2
Dana-Farber Cancer Institute
- 2020–2032
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
Principal investigator · Recruiting
Dana-Farber Cancer Institute
- 2014–2029
Principal investigator · Active not recruiting · Phase 3
AstraZeneca
- 2008–2023
Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
Principal investigator · Completed · Phase 1
AstraZeneca